QUANTIFYING PATIENT PREFERENCES FOR TYPE 2 DIABETES TREATMENTS AMONGST INDIVIDUALS IN CHINA: A DISCRETE CHOICE EXPERIMENT
Author(s)
Miao YU, PhD, MD1, Frances White, BSc2, Amy Jones, MSc2, Pam Hallworth, BSc3, Yawen Zhang, MSc4, Guo Hua, MD4, Elisabeth de Laguiche, MSc5, James Turvill, MBiolSci3.
1Department of Endocrinology, Peking Union Medical College Hospital, Beijing, China, 2Adelphi Values Patient-Centered Outcomes, Bollington, United Kingdom, 3Adelphi Research, Bollington, United Kingdom, 4Novo Nordisk Pharma Trading, Shanghai, China, 5Novo Nordisk A/S, Søborg, Denmark.
1Department of Endocrinology, Peking Union Medical College Hospital, Beijing, China, 2Adelphi Values Patient-Centered Outcomes, Bollington, United Kingdom, 3Adelphi Research, Bollington, United Kingdom, 4Novo Nordisk Pharma Trading, Shanghai, China, 5Novo Nordisk A/S, Søborg, Denmark.
OBJECTIVES: This study evaluated treatment preferences of individuals with type 2 diabetes (T2D) in China, to understand whether a once-weekly (OW) fixed-ratio combination therapy of basal insulin and a glucagon-like peptide-1 (GLP-1) receptor agonist is more aligned to individual preferences relative to other T2D treatments.
METHODS: An attributes and levels grid was developed following a targeted literature review, interviews with 10 individuals living with T2D in Italy, and feedback from an advisory panel in China. This was used to develop an online survey incorporating a discrete choice experiment, which was completed by 450 adults with T2D in China and Italy between November 2025 and March 2026. Six attributes captured administration and benefit-risk outcomes: dose preparation, frequency of administration, weight change, cardiovascular (CV) risk factors, HbA1c control, and risk of a severe hypoglycaemic (SH) event. Hierarchical Bayesian modelling was used to estimate the part-worth utilities (PWUs) for each attribute. Relative importance (RI) of attributes is reported for the China sample.
RESULTS: In total, 225 participants with T2D in China completed the survey (mean age: 52.3 years; 54% female; mean time since T2D diagnosis: 7.3 years; mean BMI: 25.4 kg/m2). Frequency of administration was the most important attribute (RI 31%), followed by weight change and risk of SH (both 19%); CV risk factors (13%), HbA1c control (11%) and dose preparation (7%) were less important. PWUs indicated a stronger preference for OW over once-daily administration, with >1 daily administration least preferred. Most respondents considered OW injections to have substantial lifestyle benefits over once-daily or twice-weekly injections.
CONCLUSIONS: Among survey participants in China with T2D, administration frequency was the most important driver of treatment preference, followed by weight change and risk of an SH event. Findings highlight the potential for OW combination therapies to better align with individual priorities by reducing treatment burden.
METHODS: An attributes and levels grid was developed following a targeted literature review, interviews with 10 individuals living with T2D in Italy, and feedback from an advisory panel in China. This was used to develop an online survey incorporating a discrete choice experiment, which was completed by 450 adults with T2D in China and Italy between November 2025 and March 2026. Six attributes captured administration and benefit-risk outcomes: dose preparation, frequency of administration, weight change, cardiovascular (CV) risk factors, HbA1c control, and risk of a severe hypoglycaemic (SH) event. Hierarchical Bayesian modelling was used to estimate the part-worth utilities (PWUs) for each attribute. Relative importance (RI) of attributes is reported for the China sample.
RESULTS: In total, 225 participants with T2D in China completed the survey (mean age: 52.3 years; 54% female; mean time since T2D diagnosis: 7.3 years; mean BMI: 25.4 kg/m2). Frequency of administration was the most important attribute (RI 31%), followed by weight change and risk of SH (both 19%); CV risk factors (13%), HbA1c control (11%) and dose preparation (7%) were less important. PWUs indicated a stronger preference for OW over once-daily administration, with >1 daily administration least preferred. Most respondents considered OW injections to have substantial lifestyle benefits over once-daily or twice-weekly injections.
CONCLUSIONS: Among survey participants in China with T2D, administration frequency was the most important driver of treatment preference, followed by weight change and risk of an SH event. Findings highlight the potential for OW combination therapies to better align with individual priorities by reducing treatment burden.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
PCR110
Topic
Patient-Centered Research
Disease
Diabetes/Endocrine/Metabolic Disorders (including obesity)